基于外泌体的ExoDx前列腺(IntelliScore)EPI检测在PSA 2-10 ng/mL初次活检男性中的临床效用
这项前瞻性随机盲法双臂临床效用研究纳入1094例患者和72名泌尿科医生,评估EPI检测对活检决策的影响。EPI组中阴性评分患者63%被建议推迟活检、74%最终推迟,阳性评分患者87%被建议活检且72%依从,高级别前列腺癌检出率较对照组提高30%,因推迟而漏诊的高级别前列腺癌估计减少49%。
要点
- EPI检测影响68%泌尿科医生的活检决策,阴性评分促进安全推迟活检。
- EPI组高级别前列腺癌检出率较对照组提高30%。
- 因推迟活检而漏诊的高级别前列腺癌估计较标准诊疗减少49%。
核心结论
- EPI检测影响推迟或进行活检的整体决策并改善患者分层。
研究设计与样本
- 前瞻性、随机、盲法、双臂临床效用研究,纳入1094例患者,来自24家泌尿科诊所的72名泌尿科医生。
主要发现
- EPI组(N=458)中93例阴性评分患者,63%被泌尿科医生建议推迟活检,74%最终推迟。
- 阳性评分患者中87%被建议活检,对医生建议的依从率为72%。
- EPI组高级别前列腺癌检出较对照组多30%,因推迟而漏诊的高级别前列腺癌估计较标准诊疗减少49%。
- 68%的泌尿科医生报告EPI检测影响了其活检决策。
- 不依从EPI结果的主要原因是PSA升高。
关键数值与推荐
- 入组患者PSA 2-10 ng/mL,基于标准临床标准考虑前列腺活检。
- 所有患者均接受EPI检测,仅EPI组获得结果用于活检决策。
临床怎么用
- 在PSA 2-10 ng/mL初次活检决策中,EPI检测可辅助识别可安全推迟活检的患者。
- 阴性EPI评分支持推迟活检,但PSA升高是不依从的主要原因,需结合临床判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ExoDx Prostate(IntelliScore) (EPI) test is a non-invasive risk assessment tool for detection of high-grade prostate cancer (HGPC) that informs whether to proceed with prostate biopsy. We sought to assess the impact of EPI on the decision to biopsy in a real-world clinical setting. METHODS: We conducted a prospective, randomized, blinded, two-armed clinical utility study that enrolled 1094 patients with 72 urologists from 24 urology practices. Patients were considered for prostate biopsy at enrollment based on standard clinical criteria. All patients had an EPI test; however, patients were randomized into EPI vs. control arms where only the EPI arm received results for their biopsy decision. RESULTS: In the EPI arm (N = 458), 93 patients received negative EPI scores of which 63% were recommended to defer biopsy by the urologist and 74% ultimately deferred. In contrast, 87% of patients with positive EPI scores were recommended to undergo biopsy with a 72% compliance rate to the urologist's recommendation. This led to detection of 30% more HGPC compared to the control arm, and we estimate that 49% fewer HGPC were missed due to deferrals compared to standard of care (SOC). Overall, 68% of urologists reported that the EPI test influenced their biopsy decision. The primary reason not to comply with EPI results was rising PSA. CONCLUSION: To our knowledge this is the first report on a PC biomarker utility study with a blinded control arm. The study demonstrates that the EPI test influences the overall decision to defer or proceed with a biopsy and improves patient stratification.
引用
- Tutrone R, Donovan MJ, Torkler P, et al. Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL. Prostate Cancer Prostatic Dis. 2020. PMID: 32382078. doi:10.1038/s41391-020-0237-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。